- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05140863
To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week, Phase 3 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Postherpetic Neuralgia
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210042
- Dermatology Hospital of Chinese Academy of Medical Sciences
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- The First Affiliated Hospital of Nanchang University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent;
- Males or females aged 18-75 years of age inclusive;
- Outpatient, Patients can not stay in the hospital overnight;
- Patients must have pain present for more than 1 months after the healing of the herpes zoster skin rash;
- At Screening, pain scale (VAS) of ≥40 mm;
Exclusion Criteria:
- Peripheral neuropathy or pain unrelated to PHN that may confuse the assessment of PHN;
- Skin conditions in the area affected by neurupathy that could alter sensation;
- Chronic systemic diseases that may affect subjects' participation in the study;
- Severe hematologic, hepatic or renal dysfunction, the subject will be excluded if:1)Neutrophils < 1.5 × 109/L, or platelet < 90 × 109/L, or hemoglobin < 100 g/L, or 2)AST/ALT > 2.5 × upper limit of normal (ULN), or TBIL > 1.5 × ULN, or 3)Estimation of glomerular filtration rate (eGFR) < 60 mL/min / 1.73 m2, or 4)Creatine kinase > 2.0 × ULN.
- Uncontrolled diabetes(HbA1c≥11.0% at screening) ;
- History of substance abuse or alcohol abuse;
- Any active infections at screening;
- HBsAg or HCV Ab positive, or HIV Ab positive, or serum TP Ab positive;
- Inability or unwillingness to discontinue any other prohibited concomitant medications (see Section 6.3);
- Patients who have undergone neurolytic or neurosurgical therapy 1 week before screening for postherpetic neuralgia;
- Failure to response to previous treatment with pregabalin at doses ≥ 300 mg/d or gabapentin at doses ≥ 1200 mg/d for treatment of PHN;
- History of allergic or medically significant adverse reaction to investigational products or their excipients, acetaminophen or related compounds;
- History of suicidal behavior or attempted suicide;
- Pregnant or preparing for pregnancy or breastfeeding during the study period, or subjects were not willing to use reliable contraceptives methods from the date of ICF signature until 28 days after the last trial drug administration, or planning to use progesterone contraceptives during this period;
- Mechanical operators who are engaged in high-altitude operations, motor vehicle driving and other dangerous machinery operators;
- Participated in another clinical study within 30 days prior to screening;
- Other conditions unlikely to participate in this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HSK16149 20mg BID
HSK16149 20mg, orally twice a day for 12 weeks
|
HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose
|
Experimental: HSK16149 40mg BID
HSK16149 40mg, orally twice a day for 12 weeks
|
HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose
|
Placebo Comparator: Placebo BID
placebo, orally twice a day for 12 weeks
|
Placebo, orally twice a day, treatment period; 12-weeks fixed dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare the change from baseline in ADPS between HSK16149 and placebo at week 12
Time Frame: Baseline and week 12
|
The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 [no pain] to 10 [worst possible pain].
The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries
|
Baseline and week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare the response rate between HSK16149 and placebo at week 12 (Proportion of subjects whose ADPS decreased by ≥30% and ≥50% from baseline )
Time Frame: Baseline and week 12
|
Ratio of Participants Responding to Treatment, as Measured by Average Daily Pain Score (ADPS) Reduction from Baseline.
The ADPS is used to determine categorical response rates.
|
Baseline and week 12
|
Compare the change from baseline in ADPS between HSK16149 and placebo at week 1 to 12
Time Frame: From week 1 to week 12
|
The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 [no pain] to 10 [worst possible pain].
The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries
|
From week 1 to week 12
|
Compare the change from baseline in Visual Analogue Scale(VAS) between HSK16149 and placebo at week 12
Time Frame: Baseline and week 12
|
VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain
|
Baseline and week 12
|
Compare the change from baseline in Short Form McGill Pain Questionnaire (SF-MPQ) between HSK16149 and placebo at week 12
Time Frame: Baseline and week 12
|
Participants rate their pain in three parts of the questionnaire, which are combined into a single pain intensity score: Part 1 - fifteen descriptors of pain intensity, on a scale of 0 (none) to 3 (severe) Part 2 - a visual analog scale (VAS), in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain Part 3 - a Present Pain Intensity index in which the participant rates present pain intensity on a scale of 0 (no pain) to 5 (most intense pain) |
Baseline and week 12
|
Compare the change from baseline in Average Daily Sleep interference score(ADSIS) between HSK16149 and placebo at week 12
Time Frame: Baseline and week 12
|
he sleep interference scores on a scale of 0-10, where 0 = pain did not interfere with sleep to 10 = pain completely interfered with sleep.
The weekly ADSIS is based on participants daily sleep interference scores
|
Baseline and week 12
|
Compare the total consumption of Acetaminophen and Paracetamol and Dihydrocodeine Tartrate between HSK16149 and placebo during the trial
Time Frame: From week 1 to week 12
|
From week 1 to week 12
|
|
Compare the change from baseline in EQ-5D-5L between HSK16149 and placebo at week 12
Time Frame: Baseline and week 12
|
The change from baseline in total EuroQol-5-Domain-5-Level health questionnaire
|
Baseline and week 12
|
AE(adverse event) to evaluate the safety of HSK16149 during the trial
Time Frame: From week 1 to week 12
|
Number and severity of AEs
|
From week 1 to week 12
|
Peak Plasma Concentration (Cmax) of HSK16149 capsules in Chinese patients with Postherpetic Neuralgia
Time Frame: Week 4,week 8,week 10,week 12
|
Week 4,week 8,week 10,week 12
|
|
Area under the plasma concentration versus time curve (AUC) of HSK16149 capsules in Chinese patients with Postherpetic Neuralgia
Time Frame: Week 4,week 8,week 10,week 12
|
Week 4,week 8,week 10,week 12
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSK16149-302
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postherpetic Neuralgia
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia ( PHN )China
-
Yonsei UniversityWithdrawnThe Evaluation of Erector Spinae Plane Block for the Pain Control of Thoracic Postherpetic NeuralgiaThoracic Postherpetic NeuralgiaKorea, Republic of
-
Bial - Portela C S.A.Completed
-
Shanghai SIMR Biotechnology Co., Ltd.CompletedPostherpetic NeuralgiaChina, Australia
-
Cairo UniversityCompleted
-
Korea University Guro HospitalUnknownNeuralgia,PostherpeticKorea, Republic of
-
Second Affiliated Hospital, School of Medicine,...CompletedPostherpetic NeuralgiaChina
-
Cubist Pharmaceuticals LLCPfizerTerminatedPostherpetic NeuralgiaUnited States
-
PfizerTerminatedPostherpetic NeuralgiaUnited States, Germany, Austria, South Africa
-
ZalicusCompletedPostherpetic NeuralgiaUnited States
Clinical Trials on HSK16149 20mg BID
-
Haisco Pharmaceutical Group Co., Ltd.Active, not recruitingPeripheral Neuropathic PainChina
-
Haisco Pharmaceutical Group Co., Ltd.UnknownDiabetic Peripheral Neuropathic PainChina
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingDiabetic Peripheral Neuropathic PainChina
-
Haisco Pharmaceutical Group Co., Ltd.Completed
-
Haisco Pharmaceutical Group Co., Ltd.CompletedHerpetic NeuralgiaChina
-
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Not yet recruiting
-
Taisho Pharmaceutical Co., Ltd.CompletedHyperphosphatemia Patients on HemodialysisJapan
-
Haisco Pharmaceutical Group Co., Ltd.CompletedRenal ImpairmentChina
-
Haisco Pharmaceutical Group Co., Ltd.The Fourth Hospital of Hebei Medical UniversityRecruitingDiabetic Neuropathies | Diabetic Neuropathy PeripheralChina
-
Seoul National University HospitalIlDong Pharmaceutical Co LtdCompletedEsophageal DiseaseKorea, Republic of